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Introduction
Migraine is a common, recurrent neurological disorder
characterised by headache that is often associated with
gastrointestinal and autonomic symptoms [1, 2]. The
chronic and debilitating nature of migraine can impede
patients’ ability to carry out normal daily activities, there-
by reducing quality of life [3, 4].
The 5-hydroxytryptamine (5-HT1B/1D) agonists, col-
lectively known as triptans, are a major advance in the
treatment of migraine. The beneficial effects of the trip-
tans in patients with migraine are related to multiple
mechanisms of action at sites implicated in the patho-
physiology of migraine.
Zolmitriptan is a 5-HT1B/1D receptor agonist that is
highly effective for the acute treatment of migraine [5, 6].
A 5-mg nasal spray formulation of zolmitriptan has recent-
ly been developed to offer patients a convenient alterna-
tive to oral tablets [7]. Nasal spray administration provides
rapid absorption directly across the nasal mucosa, result-
ing in a fast onset of action [8]. Furthermore, nasal admin-
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Abstract In phase one of the
REALIZE study, zolmitriptan nasal
spray demonstrated a significant
headache response from 10 min
post-dose and total symptom relief
from 30 min post-dose. The objec-
tive of phase two was to investigate
patients’ dosing patterns, satisfac-
tion and preference following open-
label treatment with the nasal spray.
Up to 3 attacks were treated. The
ITT population consisted of 851
patients. The median time from
onset of symptoms to treatment was
1 h 15 min (primary endpoint).
Most patients reported being satis-
fied or very satisfied with
zolmitriptan nasal spray (75.7%).
Furthermore, the majority of
patients would be willing to use
zolmitriptan nasal spray in the
future (59.8%) and preferred
zolmitriptan nasal spray over previ-
ous therapies (57.8%). Zolmitriptan
nasal spray was well tolerated.
Most patients were satisfied with
zolmitriptan nasal spray, were will-
ing to continue using it and pre-
ferred it to previous therapies.
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istration may be preferable to conventional oral prepara-
tions for those patients who experience nausea and vomit-
ing during migraine attacks, or those who have difficulty
swallowing tablets.
The efficacy and tolerability of zolmitriptan nasal
spray has been established in previous clinical trials [8, 9].
In the Real Life Intranasal Zolmitriptan Experience
(REALIZE) study, patients treated migraine attacks with
zolmitriptan nasal spray without a strictly recommended
dosing regimen [10]. This setting was designed to be more
representative of clinical practice than most clinical trials,
where patients are typically instructed to treat migraine
attacks within a specified time period or when pain sever-
ity has reached a designated level. The REALIZE study
consisted of two phases. In phase one, the efficacy of
intranasal zolmitriptan compared with placebo in the
treatment of a single migraine attack was investigated; the
primary endpoint of the study was total symptom relief
(defined as no headache pain, nausea, photophobia or
phonophobia) at 1 h post-dose. This was significantly
superior for zolmitriptan nasal spray from 30 min
onwards. Zolmitriptan nasal spray also demonstrated a
significant headache response from 10 min post-dose,
confirming the very fast onset of this formulation [10]. In
phase two, in which up to 3 migraine attacks were treated
with open-label zolmitriptan nasal spray, patients’ dosing
patterns, satisfaction and preference were assessed. The
results of the second phase of this study are reported here.
Methods
Patients
Patients aged 18–66 years with an established diagnosis of
migraine (as defined by the International Headache Society
Criteria [11]), with an age of onset of <50 years were eligible for
inclusion in the study. Patients were required to have experi-
enced at least one migraine attack per month in the previous 3
months and have the ability to differentiate between migraine
and non-migraine headaches.
Exclusion criteria included: a history of basilar, ophthalmo-
plegic or hemiplegic migraine headache, or any potential serious
neurological condition associated with headache; diagnosis or
suspicion of drug-induced or chronic daily headaches; symptoms
of, or significant risk factors for, cardiovascular disease; systolic
blood pressure of >150 mmHg or diastolic blood pressure >95
mmHg; any recent history of alcohol or drug abuse; severe
hepatic impairment; or an unacceptable adverse experience fol-
lowing previous use of any 5-HT agonist. Use of monoamine
oxidase A inhibitors, methysergide or methylergonovine was not
allowed within the 2 weeks prior to randomisation.
The study was conducted in accordance with the Declaration
of Helsinki and all investigators complied with Good Clinical
Practices. Written consent was obtained from each patient prior
to participation in the study.
Study design
This multicentre, randomised, parallel-group, two-phase study
was conducted in Canada and Germany between May 2002 and
August 2003. In phase one of the study [10], patients were ran-
domised to receive zolmitriptan 5 mg nasal spray or placebo
nasal spray in a double-blind fashion, to treat a single migraine
attack (Visit 1). Patients were instructed to use diary cards to
record efficacy data relating to the attack treated with study
medication and were asked to return to the clinic within 7 days
of the treated attack (Visit 2). Patients could then continue into
the open-label second phase of the study (reported here), in
which the next three migraine attacks were treated with
zolmitriptan nasal spray. Patients could choose to take study
medication at any time after symptom onset to treat a migraine
attack with any severity of headache pain. Patients were permit-
ted to use a second dose of zolmitriptan nasal spray or an agreed
escape medication if pain relief had not been obtained by 2 h
after the initial dose. Patients were required to return to the clin-
ic within 14 days of treating the fourth migraine attack or 6.5
months after randomisation (Visit 3). At Visits 2 and 3, the inves-
tigator reviewed each migraine attack with the patient and
ensured that diary card information had been clearly completed.
Assessments
Efficacy
The primary endpoint of the second phase of the study was the
time between onset of headache pain and dosing with zolmitrip-
tan nasal spray, as recorded in diary cards. Secondary endpoints
included: the time to a second dose of zolmitriptan nasal spray
or escape medication; patient satisfaction with zolmitriptan nasal
spray; willingness to use the formulation to treat future migraine
attacks; patient preference for zolmitriptan nasal spray over pre-
vious migraine therapies.
Satisfaction variables were assessed at the end of the study
by asking the patient direct questions regarding overall satisfac-
tion, and satisfaction with the speed of headache relief, ease of
use, convenience and reliability of zolmitriptan nasal spray.
Satisfaction was assessed using a 4-point Likert scale, where 1
indicated “dissatisfied”, 2 indicated “not satisfied or dissatis-
fied”, 3 indicated “satisfied” and 4 indicated “very satisfied”.
Patients were also asked to respond “strongly agree”, “agree”,
“disagree” or “strongly disagree” to the following statements:
(a) “I am willing to use zolmitriptan nasal spray for the treatment
of future migraine attacks”, and (b) “I prefer zolmitriptan nasal
spray over the migraine therapies I used before the study”.
Safety
Patients were encouraged to report any adverse events experi-
enced at any time during phase two of the study in the diary
cards. Any detrimental changes in the patient’s condition after
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study entry were only recorded as adverse events if occurring
during the first 24 h after taking the study drug (a period of at
least 5 times the half-life of zolmitriptan), although serious
adverse events were recorded throughout the study. The safety of
zolmitriptan nasal spray after repeated use in this study was
assessed at the end of the study from the diary card data.
Statistical methods
The safety population included all patients who treated a migraine
attack with zolmitriptan nasal spray in phase two of the study. The
intention-to-treat (ITT) population comprised those patients in the
safety population who provided post-treatment efficacy data.
Data on dosing patterns, patient satisfaction with zolmitrip-
tan nasal spray, willingness to continue using zolmitriptan nasal
spray and preference for zolmitriptan nasal spray over previous
migraine therapies were summarised using descriptive statistical
methods only. These data were not subjected to any formal sta-
tistical analysis. All adverse event data were summarised using
Medical Dictionary for Regulatory Activities (MEDRA) pre-
ferred terms and system organ classes.
Results
Patients
Of the 915 patients who treated a migraine attack with
zolmitriptan nasal spray or placebo in phase one, 886
patients (96.8%) entered phase two of the study. A total of
853 patients treated at least one migraine attack with
zolmitriptan nasal spray during phase two of the study (safe-
ty population), with 851 of these patients providing post-
treatment efficacy data (ITT population). Demographic
characteristics of the ITT population are shown in Table 1.
As expected from phase one, the phase two study population
was representative of the general migraine population (pre-
dominantly female with a mean age of about 40 years). A
total of 760 patients (89.3% of the ITT population) used
zolmitriptan nasal spray to treat 3 migraine attacks; 55
patients (6.5%) treated 2 attacks and 36 patients (4.2%)
treated one attack. In total, 2426 migraine attacks were
treated with zolmitriptan nasal spray.
Efficacy
The median time from the onset of symptoms to treatment
with zolmitriptan nasal spray was 1 h 15 min (mean 2 h 42
min; range: 0–53 h). Five hundred and eighteen attacks
(21.5%) were treated in the first 15 min, 328 (13.6%) from
>15 to 30 min, 97 (4.0%) from >30 to 45 min, 181 (7.5%)
from >45 to 60 min, and 1286 (53.4%) after 60 min. Pain
intensity at the onset of the attack and immediately before
taking study medication is shown in Table 2. Although 33%
of attacks were associated with mild pain at onset, only 7%
of attacks were treated while pain was mild. Additionally,
although 39% of attacks were associated with severe pain
when treated, only 19% were of severe pain intensity at the
onset of the attack. Almost half the attacks were of moder-
ate pain intensity at onset, and just over half were treated
with zolmitriptan nasal spray when pain intensity was mod-
erate. As the intensity of headache pain at onset increased,
the median time taken to treat the attack decreased (Fig.
1a). However, median times to treatment were longer in
attacks with initially mild or moderate pain that had wors-
ened by the time of treatment (Fig. 1b), suggesting that pain
worsened when treatment was delayed.
Of the 2426 migraine attacks treated with zolmitriptan
nasal spray, 1108 (45.7%) were followed by either a sec-
ond dose of zolmitriptan nasal spray or an agreed escape
medication. The mean time to use of further medication
was 6 h 34 min (range: 0–24 h).
In response to the overall satisfaction question (“How
satisfied are you overall with the nasal spray medication
you have used to treat your migraines in this study?”), 644
(75.7%) patients reported being “satisfied” or “very satis-
fied” with zolmitriptan nasal spray; 150 (17.6%) were
“not satisfied or dissatisfied”, 46 (5.4%) were “dissatis-
fied” and data were missing for 11 (1.3%) patients (Fig.
2). Over 75% of patients reported being “satisfied” or
“very satisfied” with zolmitriptan nasal spray for each of
the following: speed of relief (646; 75.9%); ease of use
(779; 91.5%); convenience (750; 88.1%); reliability (644;
75.7%) (Fig. 3).
In response to the question “I am willing to use
zolmitriptan nasal spray for the treatment of future











Age, years (range) 41.9 (18–66)
Height, cm (range) 167.5 (148–198)
Weight, kg (range) 69.8 (40–136)
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migraine attacks”, 509 patients (59.8%) “agreed” or
“strongly agreed”, 216 (25.4%) “disagreed” and 115
(13.5%) “strongly disagreed”. Similarly, in response to
the question “I prefer zolmitriptan nasal spray over the
migraine therapies I used before the study”, 492 (57.8%)
“agreed” or “strongly agreed”, 245 (28.8%) “disagreed”
and 103 (12.1%) “strongly disagreed”.
Table 2 Intensity of migraine headache at the onset of the attack and immediately prior to taking study medication in an open-label study
in which 851 patients could treat up to 3 attacks (attacks 2, 3 and 4) with zolmitriptan nasal spray. Patients could choose when to take
zolmitriptan nasal spray in terms of severity of the pain
Time window and Migraine attacks treated with zolmitriptan nasal spraya
headache
intensity Attack 2 Attack 3 Attack 4 Total 
(n=851), n (%) (n=815), n (%) (n=760), n (%) (n=2426), n (%)
Onset of attack
Mild 296 (34.8) 250 (30.7) 250 (32.9) 796 (32.8)
Moderate 415 (48.8) 403 (49.4) 345 (45.4) 1163 (47.9)
Severe 138 (16.2) 160 (19.6) 164 (21.6) 462 (19.0)
Not recorded 2 1(0.2) 2 1(0.2) 1 1(0.1) 5 1(0.2)
Immediately prior to taking
zolmitriptan nasal spray
Mild 58 (6.8) 58 1(7.1) 46 1(6.1) 162 1(6.7)
Moderate 496 (58.3) 434 (53.3) 390 (51.3) 1320 (54.4)
Severe 296 (34.8) 320 (39.3) 319 (42.0) 935 (38.5)
Not recorded 1 1(0.1) 3 1(0.4) 5 1(0.7) 9 1(0.4)
aAttack 1 was treated in the first phase of the REALIZE study and is not discussed in this report
Fig. 1 Median time taken between onset of headache and treatment
with zolmitriptan nasal spray for (a) 2393 migraine attacks that
were mild, moderate or severe at onset and treated within 24 h of
onset and (b) 2372 migraine attacks that were mild, moderate or
severe at onset and had either intensified or remained at the same
intensity at the time of treatment
a
b
Fig. 2 Overall patient satisfaction with zolmitriptan nasal spray fol-
lowing treatment of up to 3 migraine attacks in an open-label study.
Patients were asked “How satisfied are you overall with the nasal
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Overall, adverse events occurred in 430 (50.4%)
zolmitriptan nasal spray recipients and in 967 (39.9%)
attacks treated with zolmitriptan nasal spray. The majori-
ty of these events were of mild or moderate intensity and
resolved without intervention. Of the 644 patients who
reported being “satisfied” or “very satisfied” with
zolmitriptan nasal spray, almost half (48%) experienced
adverse events. Serious adverse events were reported in 2
patients (subileus occurring during treatment of a
migraine attack in one patient, and Norwalk virus gas-
troenteritis occurring after treatment of an attack in one
patient). Only 12 patients (1.4%) experienced adverse
events that led to premature discontinuation from the
study; these were: cardiovascular disorder (not otherwise
specified), tachycardia (not otherwise specified), nausea,
fatigue, malaise, hunger, burning sensation (not otherwise
specified), dizziness, dysgeusia, hyperaesthesia, hypoaes-
thesia, paraesthesia, somnolence, tremor, anxiety, oropha-
ryngeal swelling, throat irritation and hypertension (not
otherwise specified). Adverse events occurring in ≥2% of
attacks included dysgeusia (which was reported in 15.1%
of attacks, but led to treatment discontinuation in only 2
patients (0.2%)), throat irritation (5.8% of attacks), nasal
passage irritation (4.6%), dizziness (4.6% of attacks) and
fatigue (3.4%).
Discussion
The main focus of the second phase of the REALIZE
study was patient experience with zolmitriptan nasal spray
without a dictated regimen for dosing. Patients were able
to treat migraine attacks of any intensity, without a fixed
time between symptom onset and dosing. Hence, this pro-
vided an important indication of patients’ dosing patterns
with zolmitriptan nasal spray in a true clinical practice
setting. The open-label treatment of three attacks was
deemed necessary to allow patients to become accustomed
to nasal administration, before making any valid judge-
ments about satisfaction or preference.
The results of the study indicate that most patients
treat at either <30 min (35%) or >60 min (53%) after
attack onset. Only a small proportion of attacks were
treated while pain was mild (7%), even though 33% of
attacks were of mild pain intensity at onset, indicating that
a substantial proportion of patients were reluctant to treat
when pain intensity was mild. A relatively high proportion
of migraine attacks were treated when pain was severe
(39%), although only 19% of attacks began with severe
pain, indicating that when patients waited to treat,
headache pain often intensified. The results of this study
suggest that the greater the intensity of pain at onset of the
attacks, the sooner the attack is treated. Clinical studies
have shown that treating a migraine early, while pain is
mild, results in the best response to therapy [12–14]. Data
reported by Klapper et al. demonstrated the efficacy of
zolmitriptan conventional tablets, taken while headache
pain was mild, in terms of headache response and reduc-
tion in progression to more severe pain intensity [15].
Patient satisfaction with regard to ease of use and con-
venience of zolmitriptan nasal spray was high in the sec-
ond phase of the REALIZE study, with 88%–92% of
patients “satisfied” or “very satisfied” with these aspects
of treatment. If patients are made aware of the potential
benefits of treating before pain intensifies, the ease of use
and convenience that patients associate with zolmitriptan
nasal spray could help to ensure that patients use the
treatment in a way that achieves optimal efficacy.
Regardless of when patients chose to treat a migraine
attack, approximately three quarters (76%) were “very
satisfied” or “satisfied” with zolmitriptan nasal spray
overall. These results follow on from phase one of the
REALIZE study, which demonstrated the efficacy and fast
onset of action of zolmitriptan nasal spray [10]. In the pre-
sent study, the majority of patients (about 76%) were
“very satisfied” or “satisfied” with zolmitriptan nasal
spray with regard to speed of relief and reliability. Such
attributes have been previously identified as being impor-
tant characteristics of an acute migraine therapy [16–18].
Furthermore, the majority of patients would be willing to
Fig. 3 Patient satisfaction with the speed of relief, ease of use, con-
venience and reliability of zolmitriptan nasal spray following treat-
ment of up to 3 migraine attacks in an open-label study (n=851)
Very satisfied
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Not satisfied or dissatisfied
Dissatisfied
No response









use zolmitriptan nasal spray in the future and preferred
zolmitriptan nasal spray over previous therapies.
Treatment satisfaction with zolmitriptan nasal spray
has also been reported in two studies conducted at differ-
ent clinics in Sweden [19, 20]. The first study was based
on patients’ cumulative experience of using the nasal
spray to treat up to 6 consecutive migraine attacks [19].
The majority of the 232 patients (69%) wished to contin-
ue treatment with the nasal spray at the end of the study.
The most common reasons given for wanting to continue
using zolmitriptan nasal spray were: fast onset of action
(75%); only needing one dose (58%); and achieving com-
plete relief from migraine pain (56%). The second study
involved 117 patients who had tried zolmitriptan nasal
spray on at least one occasion for the treatment of
migraine [20]. Seventy percent of patients wished to con-
tinue using zolmitriptan nasal spray; the main reasons
were effectiveness and fast onset of action (complete
relief from headache pain was achieved within one hour in
65% of patients). Patient satisfaction was also assessed as
a secondary endpoint in a long-term safety and efficacy
trial of zolmitriptan nasal spray; overall satisfaction was
rated as “excellent” or “good” by most patients [9].
Zolmitriptan nasal spray was well tolerated in phase
two of the REALIZE study, with very few patients with-
drawing from the study due to adverse events. The most
common adverse event, dysgeusia, was typically report-
ed as mild and did not appear to be troublesome to
patients.
Conclusions
The satisfaction data from the present study demonstrate
that zolmitriptan nasal spray is effective in the acute treat-
ment of migraine and preferred to other therapies by the
majority of patients. The performance of zolmitriptan
nasal spray in the clinical practice setting suggests that it
offers patients and physicians a significant advance in
migraine therapy.
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